Chile vs Israel: Pneumococcal conjugate second or third-dose vaccines (PCVc)
Chile
94.0%
in 2025
Israel
94.0%
in 2025
Chile rank
44th
Israel rank
44th
Pneumococcal conjugate second or third-dose vaccines (PCVc) over time
- Chile
- Israel
How they compare
Chile currently reports 94.0% against 94.0% in Israel, a difference of 0.0%.
Across all 18 years both countries report, Israel has been ahead every year.
Chile ranks 44th and Israel ranks 44th of 192 countries.
Israel has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Chile | Israel | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 0.0% | 0.0% | 0.0% | β |
| 2010s | 77.1% | 84.4% | 7.3% | Israel |
| 2020s | 92.3% | 94.2% | 1.8% | Israel |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pneumococcal conjugate second or third-dose vaccines (pcvc), Chile or Israel?
- Chile, at 94.0% against 94.0% in Israel as of 2025.
- What is the difference in pneumococcal conjugate second or third-dose vaccines (pcvc) between Chile and Israel?
- 0.0%, with Chile ahead.
- How many years of comparable data are there for Chile and Israel?
- 18 years are reported by both, from 2008 to 2025.
- How do Chile and Israel rank globally for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Chile ranks 44th and Israel ranks 44th of 192 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid refreshes it automatically from the source and publishes the full history for both places.